Brain Drug Targeting
The Future of Brain Drug Development
- Publisher's listprice GBP 201.00
-
101 726 Ft (96 882 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 20 345 Ft off)
- Discounted price 81 381 Ft (77 506 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
101 726 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Cambridge University Press
- Date of Publication 31 May 2001
- ISBN 9780521800778
- Binding Hardback
- No. of pages372 pages
- Size 254x182x24 mm
- Weight 933 g
- Language English 0
Categories
Short description:
This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting.
MoreLong description:
The thesis of this innovative and challenging book, first published in 2001, is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system.
Review of the hardback: '... a book that will become a standard on drug targeting to the brain ... a must for everybody who works in the field of brain drug delivery in academia as well as in the pharmaceutical industry.' W. Kamphorst, www.bmjbookshop.com
Table of Contents:
Preface; 1. Drug targeting, drug discovery, and brain drug development; 2. Invasive drug delivery; 3. Lipid-mediated transport and carrier-mediated transport of small molecules; 4. Receptor-mediated transcytosis of peptides; 5. Vector discovery: genetically-engineered trojan horses for drug targeting; 6. Linker strategies: the engineering of multi-functional drug formulations; 7. Protein neuropathies and peptide radiopharmaceuticals; 8. Antisense neurotherapeutics and imaging gene expression in vivo; 9. Gene therapy of the brain; 10. Blood-brain barrier genomics; Epilogue; Bibliography.
More
